North America Unit Dose Manufacturing Market To Reach $56.22 Billion By 2030

North America Unit Dose Manufacturing Market Growth & Trends

The North America unit dose manufacturing market size is expected to reach USD 56.22 billion in 2030 and is projected to grow at a CAGR of 11.23% from 2025 to 2030. The rapidly growing pharmaceutical industry and rising demand for unit doses are factors driving the market.

Single-dose packaging has certainly become one of the most popular recent trends. The most obvious benefit is its ease of use and improved medication management, as they can be prescribed by the unit, ensuring that the person taking it does not exceed the prescribed dose. Stick packs are unique in the way that they can be used to package a variety of items, both dry and wet.

Measuring cups, teaspoons, tablespoons, and multi-dose containers for oral liquids and eye drops have been already seen. The current patient is seeking convenience. Doctors are also appreciating the importance of unit dose in prescription writing since it allows them to prescribe controlled substance oral liquid without concern of abuse as unit doses address the issue. It also enables pharmacists to store oral liquids in a secure manner, which is a significant additional benefit. Nearly every single unit dose oral solid or multiple-dose oral liquid could be transformed to a unit dose oral liquid due to this innovation.

However, owing to the COVID-19 pandemic's repercussions, the unit dose manufacturing market increased at a modest 11.0% year over year in 2020. By the end of 2020, the market started to recover. COVID-19-related illnesses are being treated using unit dosages. Hospitals have updated and implemented various new standard operating procedures to protect both patients and healthcare workers. As a consequence, it's crucial to consider out viral transmission by airborne transmission or direct contact. When unit dose medicines are used, some of the risks involved with handling and pouring doses from the same bottle are reduced. 

 Request a free sample copy or view report summary: North America Unit Dose Manufacturing Market Report

North America Unit Dose Manufacturing Market Report Highlights

• The outsourcing segment led the market with the largest revenue share of 60.13% in 2024. Unit doses lead to the minimization of credits for drugs coupled with greater control by a pharmacist over work patterns and schedules.

• The solid unit dose segment led the market with the largest revenue share of 49.71% in 2024. In 2018, oral solid dosage medicines accounted for 53% of all new pharmaceuticals approved by the FDA.

• The independent pharmacies segment led the market with the largest revenue share of 37.83% in 2024.

• The hospitals segment accounted for the second-largest revenue share in 2024. Unit dose packaging ensures precise dosing, reduces the possibility of medication errors, and supports medication safety protocols within hospital settings.

North America Unit Dose Manufacturing Market Segmentation

Grand View Research has segmented the North America unit dose manufacturing market report based on the sourcing, product, end use, and country:

North America Unit Dose Manufacturing Sourcing Outlook (Revenue, USD Million, 2018 - 2030)

• In-house

• Outsourcing

North America Unit Dose Manufacturing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Liquid Unit Dose

• Solid Unit Dose

• Others

North America Unit Dose Manufacturing End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Independent Pharmacies

• Long Term Care Facility

• Hospitals

• Others

North America Unit Dose Manufacturing Country Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

List of Key Players of North America Unit Dose Manufacturing Market

• Catalent Inc.

• Unither Pharmaceuticals

• Thermo Fisher Scientific

• Corden Pharma

• Mikart LLC

• LTS LOHMANN Therapie-Systeme AG (TapeMark)

• Renaissance Lakewood LLC

• Medical Packaging Inc.

• American Health Packaging

• PCI Pharma Services

• Amcor PLC

• Bristol-Myers Squibb

• AbbVie Inc.

• Merck & Co. Inc.

• Pfizer Inc.